Search Result

Results for "

in vivo efficacy

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (4) Adrenergic Receptor (1) Akt (3) Amyloid-β (3) Androgen Receptor (1) Angiotensin-converting Enzyme (ACE) (1) Antibiotic (4) Apoptosis (18) Arf Family GTPase (1) Autophagy (2) Bacterial (16) Bcl-2 Family (4) Bcr-Abl (1) Biochemical Assay Reagents (1) Btk (1) c-Fms (1) c-Kit (1) c-Met/HGFR (2) c-Myc (2) Calcium Channel (3) Cannabinoid Receptor (2) Caspase (4) CDK (3) Choline Kinase (1) COX (1) CXCR (1) DNA/RNA Synthesis (9) Drug Derivative (3) Drug Isomer (1) Drug-Linker Conjugates for ADC (1) DYRK (2) EGFR (5) Endogenous Metabolite (4) Epigenetic Reader Domain (1) ERK (3) FGFR (2) GABA Receptor (2) GLUT (2) Glycosidase (1) HBV (1) HDAC (5) HIF/HIF Prolyl-Hydroxylase (1) Histamine Receptor (3) Histone Acetyltransferase (1) Histone Demethylase (1) Histone Methyltransferase (2) HIV (2) HSP (1) iGluR (2) Indoleamine 2,3-Dioxygenase (IDO) (1) Influenza Virus (1) Interleukin Related (1) Isotope-Labeled Compounds (2) Itk (1) JAK (2) JNK (1) Liposome (1) Lipoxygenase (1) LPL Receptor (2) MAP4K (2) MDM-2/p53 (1) Melanocortin Receptor (1) MetAP (1) mGluR (1) Mitophagy (1) Mixed Lineage Kinase (1) MNK (1) Molecular Glues (3) mTOR (3) NADPH Oxidase (1) Necroptosis (2) NF-κB (4) NOD-like Receptor (NLR) (2) Opioid Receptor (1) P2Y Receptor (1) PAK (1) Parasite (3) PARP (5) PD-1/PD-L1 (5) PDGFR (3) Phosphodiesterase (PDE) (3) Photosensitizer (1) PI3K (3) PI4K (1) Pim (1) Potassium Channel (2) PPAR (1) Prostaglandin Receptor (2) PROTACs (5) PTEN (1) Raf (1) Ras (1) Reactive Oxygen Species (ROS) (2) Reference Standards (1) RET (1) Reverse Transcriptase (2) RIP kinase (2) ROR (1) Serotonin Transporter (3) SHP2 (1) Sodium Channel (1) STING (1) TAM Receptor (1) TNF Receptor (1) Topoisomerase (5) Trk Receptor (1) URAT1 (1) VEGFR (3) YAP (1) α-synuclein (1) γ-secretase (2)
By Research Areas:	Cancer (75) Cardiovascular Disease (5) Endocrinology (1) Infection (24) Inflammation/Immunology (21) Metabolic Disease (13) Neurological Disease (23)
Click Chemistry:	PROTAC Synthesis (1) Alkynes (1)
Oligonucleotides:	Cationic Lipids (1)

146

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

Targets Recommended: Dan family AIM2 NEKs CD44

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-151561

WM382	Parasite	Infection
WM382 is an orally active and potent dual plasmepsin IX/X (PMIX/X) inhibitor with IC₅₀ values of 1.4 nM and 0.03 nM, respectively. WM382 has robust in vivo efficacy at multiple stages of the malaria parasite life cycle and an excellent resistance profile .

HY-132893

AZ14145845	TAM Receptor	Cancer
AZ14145845 is a highly selective type I1/2 dual Mer/Axl kinase inhibitor with in vivo efficacy.

HY-155250

Antibacterial agent 154	Bacterial	Infection
Antibacterial agent 154 (compound 7) is a derivative of Fluoroqinolones and is an orally effective antibacterial agent. Antibacterial agent 154 inhibits Gram-positive and Gram-negative bacteria. Antibacterial agent 154 demonstrated in vivo efficacy in a mouse model of staphylococcal sepsis .

HY-179024

NP3-742	NOD-like Receptor (NLR) Interleukin Related	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
NP3-742 is an orally active NLRP3 inhibitor that binds to the NLRP3 NACHT domain. NP3-742 inhibits IL-1β release with IC₅₀s of 6 nM and 47 nM in both the cellular and whole blood assays, respectively. NP3-742 is highly selective against a panel of more than 50 enzymes, receptors and sodium and calcium channels. NP3-742 can be used for the study of gout, cardiovascular disease or osteoarthritis .

HY-155146

Anticancer agent 146	Necroptosis	Cancer
Anticancer agent 146 (compound 1.19) is a necroptosis inducer. Anticancer agent 146 has anti-tumor efficacy in the mouse MDA-MB-231 xenograft model .

HY-178504

Lug-15	Bacterial	Infection
Lug-15 is a rapid bactericidal agent. Lug-15 exhibits strong antibacterial activity against both Gram-positive and Gram-negative bacteria, including drug-resistant strains. Lug-15 rapidly kills bacteria primarily through membrane disruption and had a very low propensity to induce bacterial resistance. Lug-15 demonstrates low hemolytic toxicity and significant therapeutic potential in various infection models. Lug-15 can be used for research on combating infections caused by multi-drug resistant bacteria .

HY-178762S

RIPK1-IN-35	RIP kinase Necroptosis	Inflammation/Immunology
RIPK1-IN-35 is a selective and orally active RIPK1 inhibitor with an IC₅₀ of 5.33 nM. RIPK1-IN-35 has a potent protective effect against necroptosis in both human and murine cells. RIPK1-IN-35 shows good therapeutic effects in both TNF-α-induced systemic inflammatory response syndrome and DSS (HY-116282C)-induced inflammatory bowel disease models. RIPK1-IN-35 can be used to the study of inflammatory diseases related to necroptosis .

HY-179246

CXT29	COX Prostaglandin Receptor	Cardiovascular Disease Neurological Disease Inflammation/Immunology
CXT29 is an orally active COX-2 inhibitor and a thromboxane A₂ receptor (TP) antagonist. CXT29 exhibits COX inhibitory activity and selectivity, with IC₅₀ values of 13 and 722 nM for COX-2 and COX-1 respectively. CXT29 inhibits platelet aggregation induced by U-46619 (HY-108566) (a TP agonist), with an IC₅₀ of 96 nM. CXT29 effectively inhibits the production of TXB₂ and PGE₂, significantly reducing platelet aggregation and inflammatory pain in mice. CXT29 can be used for research on inflammatory pain and cardiovascular diseases .

HY-157302

c-Met-IN-21	c-Met/HGFR	Cancer
c-Met-IN-21 (compound 54) is a c-met inhibitor with an IC₅₀ value of 0.45? nM, and shows anti-tumor efficacy in vivo .

HY-W580812

(R)-3-Aminopyrrolidine-2,5-dione	Drug Derivative	Neurological Disease
(R)-3-Aminopyrrolidine-2,5-dione is a potential anticonvulsant agent and its derivatives have comparable in vivo efficacy .

HY-141896

RET-IN-7	RET	Cancer
RET-IN-7 demonstrates potent in vitro RET kinase inhibition and robust in vivo efficacy in RET-driven tumor xenografts upon multiday dosing in mice.

HY-124674

CCT365623	Lipoxygenase	Cancer
CCT365623 is a potent and orally active LOX inhibitor with an IC₅₀ of 0.9 μM. CCT365623 has potent anti-metastatic efficacy in vivo .

HY-112240

Antibacterial agent 104	Antibiotic Bacterial	Infection
Antibacterial agent 104 (Compound 7) is a potent antibacterial agent. Antibacterial agent 104 displays excellent antibacterial activity in vitro and good efficacy in vivo against MRSA .

HY-107561

A-943931 hydrochloride	Histamine Receptor	Inflammation/Immunology
A-943931 (Compound 10) is a histamine H₄ receptor antagonists. A-943931 has improved pharmacotropic and in vivo efficacy in models of pain and inflammation. A-943931 can be used in vivo anti-inflammatory and anti-nociception research .

HY-130511

FCE 22250	Bacterial	Infection
FCE 22250 is a 3-azinomethylrifamycin with long-term in vivo persistence and good oral absorption. FCE 22250 shows superior efficacy against a broad antimicrobial spectrum including mycobacteria .

HY-118269

OSI-296	c-Met/HGFR	Cancer
OSI-296 is a potent, oral and selective inhibitor of cMET and RON kinases. OSI-296 shows in vivo efficacy in MKN45 tumor xenografts models and well tolerated .

HY-14140

BPR-890	Cannabinoid Receptor	Metabolic Disease
BPR-890 is a potent agonist of CB1. BPR-890 exhibits excellent CB2/1 selectivity and has in vivo efficacy in diet-induced obese mouse model .

HY-156511

ETC-168	MNK	Cancer
ETC-168 is a selective and oral active MNK inhibitor with the IC₅₀ values of 23 and 43 nM against MNK1 and MNK2, respectively. ETC-168 shows antiproliferative efficacy in vivo and in vitro .

HY-146185

CCT373566	Molecular Glues Bcl-2 Family	Cancer
CCT373566 is a potent and orally active molecular glue degrader of transcriptional repressor BCL6, with an IC₅₀ of 2.2 nM. CCT373566 shows strong antiproliferative efficacy in vitro and reduction in tumor growth in vivo .

HY-121827

LH21 1 Publications Verification	Cannabinoid Receptor	Metabolic Disease
LH-21 is a potent in vivo neutral cannabinoid CB1 receptor antagonist. LH-21 reduces food intake and body weight gain in obese Zucker rats. , and displays efficacy as a feeding inhibitor .

HY-W112166A

4,4'-Dicyanostilbene	Bacterial	Infection
4,4'-Dicyanostilbene (compound 43) is a potent antimalarial agent against the Dd2 strain, with an EC₅₀ of 27 nM. 4,4'-Dicyanostilbene exhibits in vivo efficacy against methicillin-resistant Staphylococcus aureus (MRSA) .

HY-162144

BDM91288	Bacterial	Infection
BDM91288 is an orally active AcrB efflux pump inhibitor of pyridinium piperazine. BDM91288 can enhance the in vivo efficacy of levofloxacin (HY-B0330) in the treatment of Klebsiella pneumoniae pulmonary infection in mouse models .

HY-149430

YIAD-0205	Amyloid-β	Neurological Disease
YIAD-0205 is an orally available Aβ(1?42) aggregation inhibitor. YIAD-0205 demonstrated in vivo efficacy in an AD transgenic mouse model with five familial AD mutations (5XFAD) .

HY-163149

AB-452	HBV	Infection
AB-452, a Dihydroquinolizinone (DHQ) analogue, is a potent and orally active HBV RNA destabilizer. AB-452 inhibits PAPD5/7 proteins in vitro with good in vivo efficacy in a chronic HBV mouse model .

HY-19277

CP-114271	Adrenergic Receptor	Metabolic Disease
CP-114271 is a potent selective β3-adrenergic receptor agonist. CP-114271 possesses an in vivo efficacy in rodent models. CP-114271 can be used for obesity research .

HY-159881

SHS206	Mitophagy	Metabolic Disease
SHS206 (compound 6n) is an orally active mitochondrial uncoupler that reduces hepatic triglyceride levels. SHS206 exhibits in vivo efficacy in the GAN mouse model and shows inhibitory effects on metabolic dysfunction-associated steatohepatitis (MASH) .

HY-146397

TD-802	PROTACs Androgen Receptor	Cancer
TD-802 (Compound 33c) is an androgen receptor (AR) PROTAC degrader with good microsomal stability. TD-802 has good antitumor efficacy in vivo and can be used for metastatic castration-resistant prostate cancer research .

HY-P99579

Tamtuvetmab AT-005	NF-κB	Cancer
Tamtuvetmab (AT-005) is a caninised blontuvetmab against CD52. Tamtuvetmab increases progression-free survival (PFS), exhibits in vivo efficacy in dogs with naïve T-cell lymphoma (LSA). Tamtuvetmab has been approved by veterinary .

HY-130628

PAK4-IN-1	PAK	Cancer
PAK4-IN-1 (Compound 19) is a potent, selective, orally active PAK4 inhibitor with robust anti-tumor efficacy in vivo. PAK4-IN-1 is stable under both acidic and neutral conditions .

HY-176753

Lipid 20b	Liposome	Inflammation/Immunology
Lipid 20b is a thiophene ionizable cationic lipid. Lipid 20 b can be used to generate lipid nanoparticles (LNPs) for the delivery of mRNA in vivo. Lipid 20b can be studied in research for enhancing mRNA vaccine delivery and transfection efficacy .

HY-172453

XW-032	Indoleamine 2,3-Dioxygenase (IDO)	Cancer
XW-032 is an apo-IDO1 inhibitor, with an IC₅₀ of 21 nM. XW-032 (TGI = 63%) exhibits potent in vivo anti-tumor efficacy in the CT26 syngeneic mouse model and is expected to be applied in the research of the field of cancer .

HY-163073

Anti-MRSA agent 9	Bacterial	Infection
Anti-MRSA agent 9 (compound 39) shows antibacterial effects against clinically isolated methicillin-resistant Staphylococcus aureus (MRSA) with MIC values of 1 μg/ml. Anti-MRSA agent 9 also shows anti-MRSA efficacy in vivo .

HY-152033

URAT1 inhibitor 4	URAT1 GLUT	Metabolic Disease
URAT1 inhibitor 4, a Lesinurad derivative, is a potent and orally active URAT1 inhibitor with an IC₅₀ of 7.56 μM. URAT1 inhibitor 4 has higher in vivo urate-lowering efficacy than Lesinurad (HY-15258) .

HY-P990083

Tegoprubart AT-1501	TNF Receptor	Cancer
Tegoprubart is a monoclonal antibody directed against CD40 ligand (CD40L), a key mediator of costimulation. Inhibition of CD40L reduces cellular and antibody-mediated immunity and creates a more tolerant immune environment. Tegoprubart was demonstrated to have in vivo efficacy in transplantation animal models.

HY-108974

Drotaverine hydrochloride	Phosphodiesterase (PDE) Calcium Channel	Neurological Disease
Drotaverine hydrochloride is a type 4 cyclic nucleotide phosphodiesterase (PDE4) inhibitor and an L-type voltage-dependent calcium channel (L-VDCC) blocker, blocks the degradation of 3',5'-cyclic adenosine monophosphate. Drotaverine (hydrochloride) exhibits in vivo antispasmodic efficacy without anticholinergic effects.

HY-149759

SHP2-IN-23	SHP2 ERK	Cancer
SHP2-IN-23 (compound 30) is an orally active SHP2 inhibitor (IC₅₀=38 nM) with excellent in vivo efficacy and pharmacokinetic profiles. SHP2-IN-23 inhibits ERK phosphorylation with IC₅₀=5 nM .

HY-143444

JAK-IN-20	JAK	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
JAK-IN-20 is a potent, pan and orally active JAK inhibitor with an IC₅₀s of 7 nM, 5 nM, 14 nM for JAK1, JAK2, JAK3, respectively. JAK-IN-20 shows excellent pharmacokinetics and displays anti-inflammatory efficacy in vivo .

HY-162171

Antibacterial agent 179	Bacterial	Infection
Antibacterial agent 179 (Compound 23) is a potent antibacterial agent, which effectively kills both Gram-negative and Gram-positive bacteria. Antibacterial agent 179 shows potent in vivo antibacterial efficacy in murine corneal infection models caused by Staphylococcus aureus or Pseudomonas aeruginosa .

HY-132822A

Ivospemin hydrochloride SBP-101 hydrochloride	Drug Derivative	Cancer
Ivospemin (SBP-101) hydrochloride is an antineoplastic spermine analog. Ivospemin hydrochloride has shown efficacy in slowing pancreatic and ovarian tumor progression in vitro and in vivo. Ivospemin hydrochloride shows modest induction of polyamine catabolism, but stronger repression of ornithine decarboxylase activity. Ivospemin hydrochloride is promising for research of cancers .

HY-132822

Ivospemin SBP-101	Drug Derivative	Cancer
Ivospemin (SBP-101) is an antineoplastic spermine analog. Ivospemin has shown efficacy in slowing pancreatic and ovarian tumor progression in vitro and in vivo. Ivospemin shows modest induction of polyamine catabolism, but stronger repression of ornithine decarboxylase activity. Ivospemin is promising for research of cancers .

HY-162763

FLQY2	Apoptosis	Cancer
FLQY2 is a camptothecin analog that exhibits outstanding antitumor efficacy against various solid tumors. FLQY2 possesses both in vitro and in vivo anti-pancreatic cancer activity, inhibiting cell proliferation, colony formation, inducing apoptosis, and causing cell cycle arrest at nanomolar concentrations .

HY-P4072

(D)-PPA 1	PD-1/PD-L1	Cancer
(D)-PPA 1 is a hydrolysisresistant d-peptide antagonist. (D)-PPA 1 serves as a potent PD-1/PD-L1 inhibitor. (D)-PPA 1 binds to PD-1 with the affinity 0f 0.51 μM with in vitro and in vivo efficacy .

HY-160649

MC-Gly-Gly-Phe-Gly-GABA-Exatecan	Drug-Linker Conjugates for ADC Topoisomerase	Cancer
MC-Gly-Gly-Phe-Gly-GABA-Exatecan is an agent linker conjugate for ADC, with an inhibitor for Topoisomerase Exatecan (HY-13631) with IC₅₀ of 22 μM. MC-Gly-Gly-Phe-Gly-GABA-Exatecan targets various antibodies, exhibits cytotoxic and antitumor efficacy in vitro and in vivo .

HY-14262

Vilazodone 5 Publications Verification EMD 68843; SB659746A	5-HT Receptor Serotonin Transporter	Neurological Disease
Vilazodone (EMD 68843; SB 659746A) is a potent, selective and orally active serotonin reuptake inhibitor (SSRI) and partial 5-HT₁A receptor agonist. Vilazodone exhibits antidepressant efficacy in vivo can be used for the research of major depressive disorder (MDD) and affective disorders .

HY-149429

PPARδ agonist 9	PPAR	Metabolic Disease
PPARδ agonist 9 (compound 21) is a PPARδ agonist (EC₅₀: 3.6 nM). PPARδ agonist 9 has in vivo efficacy, reducing serum levels of MCP-1 in mice and significantly inhibiting atherosclerosis progression in the LDLr-KO model (inhibition rate: 50-60%) .

HY-P4072A

(D)-PPA 1 TFA	PD-1/PD-L1	Cancer
(D)-PPA 1 TFA is a hydrolysisresistant d-peptide antagonist. (D)-PPA 1 TFA serves as a potent PD-1/PD-L1 inhibitor. (D)-PPA 1 TFA binds to PD-1 with the affinity 0f 0.51 μM with in vitro and in vivo efficacy .

HY-145688

HDAC-IN-33	HDAC	Cancer
HDAC-IN-33 is a potent HDAC inhibitor with IC₅₀s of 24, 46, and 47 nM for HDAC1, HDAC2 and HDAC6, respectively. HDAC-IN-33 possesses potent antiproliferation activities against tumor cells. HDAC-IN-33 shows potent antitumor efficacy in vivo That trigger antitumor immunity .

HY-146697

IHMT-TRK-284	Trk Receptor c-Fms PDGFR Bcr-Abl c-Kit Apoptosis	Cancer
IHMT-TRK-284 (Compound 34) is a potent, orally active type II TRK kinase inhibitor with IC₅₀ values of 10.5, 0.7, and 2.6 nM to TRKA, B, and C respectively. IHMT-TRK-284 displays great selectivity profile in the kinome and good in vivo antitumor efficacies .

HY-145687

HDAC-IN-32	HDAC	Cancer
HDAC-IN-32 is a potent HDAC inhibitor with IC₅₀s of 5.2, 11, and 28 nM for HDAC1, HDAC2 and HDAC6, respectively. HDAC-IN-32 possesses potent antiproliferation activities against tumor cells. HDAC-IN-32 shows potent antitumor efficacy in vivo That trigger antitumor immunity .

HY-108974S

Drotaverine-d10 hydrochloride	Isotope-Labeled Compounds Phosphodiesterase (PDE) Calcium Channel	Neurological Disease
Drotaverine-d₁₀ (hydrochloride) is the deuterium labeled Drotaverine hydrochloride. Drotaverine hydrochloride is a type 4 cyclic nucleotide phosphodiesterase (PDE4) inhibitor and an L-type voltage-dependent calcium channel (L-VDCC) blocker, blocks the degradation of 3',5'-cyclic adenosine monophosphate. Drotaverine hydrochloride exhibits in vivo antispasmodic efficacy without anticholinergic effects .

Cat. No.	Product Name

HY-L177

Antibody Inhibitor Library

1,467 compounds

Antibody inhibitors are compounds with the same activity as the original therapeutic antibodies, which can be used as positive controls for drug efficacy evaluation and other studies. Antibody inhibitors can also assist in verifying the functional activity of the target protein. These antibody inhibitors are active in vivo and can achieve certain physiological functions by blocking or neutralizing target proteins, such as CD20, HER2, EGFR, VEGFR, TNF-α, etc. In drug screening, antibody inhibitor-based screening can be carried out to identify active compounds targeting target proteins and target diseases.

MCE can provide 1,467 antibody inhibitors that can be used for drug development in cancer, immunity, infection and other hot research areas.

Cat. No.	Product Name	Target	Research Area

HY-P4072A

(D)-PPA 1 TFA	PD-1/PD-L1	Cancer
(D)-PPA 1 TFA is a hydrolysisresistant d-peptide antagonist. (D)-PPA 1 TFA serves as a potent PD-1/PD-L1 inhibitor. (D)-PPA 1 TFA binds to PD-1 with the affinity 0f 0.51 μM with in vitro and in vivo efficacy .

HY-P4072

(D)-PPA 1	PD-1/PD-L1	Cancer
(D)-PPA 1 is a hydrolysisresistant d-peptide antagonist. (D)-PPA 1 serves as a potent PD-1/PD-L1 inhibitor. (D)-PPA 1 binds to PD-1 with the affinity 0f 0.51 μM with in vitro and in vivo efficacy .

HY-P3350

LS-BF1	Bacterial	Infection
LS-BF1 is a stable and low toxic cationic antimicrobial peptide. LS-BF1 displays broad spectrum of antibacterial activity, including the challenging ESKAPE pathogens, by cell membrane disruptive mechanism. LS-BF1 shows good in vivo efficacy for elimination of bacteria in a mouse infection model[1].

Cat. No.	Product Name	Target	Research Area

HY-P99579

Tamtuvetmab AT-005	NF-κB	Cancer
Tamtuvetmab (AT-005) is a caninised blontuvetmab against CD52. Tamtuvetmab increases progression-free survival (PFS), exhibits in vivo efficacy in dogs with naïve T-cell lymphoma (LSA). Tamtuvetmab has been approved by veterinary .

HY-P990083

Tegoprubart AT-1501	TNF Receptor	Cancer
Tegoprubart is a monoclonal antibody directed against CD40 ligand (CD40L), a key mediator of costimulation. Inhibition of CD40L reduces cellular and antibody-mediated immunity and creates a more tolerant immune environment. Tegoprubart was demonstrated to have in vivo efficacy in transplantation animal models.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N2909

Aurantiamide	Alkaloids Classification of Application Fields Other Alkaloids Source classification Umbelliferae Plants Inflammation/Immunology Disease Research Fields Carphephorus corymbosus (Nutt.) Torr. & A.Gray	NF-κB RIP kinase Mixed Lineage Kinase
Aurantiamide is a non-covalent, orally active, blood-brain-permeable GRPR selective antagonist with anti-inflammatory and neuroprotective effects. Aurantiamide reduces inflammation and oxidative stress in renal tissue by inhibiting GRPR-mediated renal necrosis pathways (such as RIPK3/MLKL signaling) and NF-κB inflammatory pathways, exerting anti-acute kidney injury and endothelial function activities. Aurantiamide also inhibits the M1 polarization of microglia and inhibits NLRP3 activation, thereby improving AD mouse models. Aurantiamide has in vivo inhibitory efficacy in acute kidney injury models such as ischemia/reperfusion, sepsis, and hypertension models .

HY-N12044

Asparanin A	Polysaccharides Liliaceae Source classification Plants Saccharides Asparagus officinalis L.	Apoptosis
Asparanin A is an apoptosis inducer with anticancer activity. Asparanin A induces cell cycle arrest in the G0/G1 phase through mitochondria and PI3K/AKT signaling pathways, inhibiting cancer cell growth. Asparanin A also demonstrated in vivo efficacy in a mouse xenograft model of Ishikawa endometrial carcinoma, significantly inhibiting tumor growth .

HY-122292

Celastramycin A	Animals Antibiotics Source classification	Antibiotic Bacterial
Celastramycin A is an antibiotic isolated from Streptomyces MaB-QuH-8, which exhibits antimicrobial activity against series of gram-negative bacteria and mycobacteria, with MICs between 0.05-3.1 μg/ml . Celastramycin A exhibits immunosuppressing efficacy in ex vivo Drosophila through immune deficiency pathway (IC₅₀ of 0.008 μg/ml), inhibits the immunoresponse in human innate immunity through TNF-α signaling, inhibits IL-8 production in HUEVCs with IC₅₀ of 0.06 μg/ml .

HY-N7545

Protorubradirin	Microorganisms Antibiotics Source classification Other Antibiotics	Antibiotic Reverse Transcriptase
Protorubradirin is an antibiotic that can be isolated from Streptomyces achromogenes var. rubradirin together with Rubradirin. Protorubradirin has inhibitory activity against HIV reverse transcriptase. In vitro studies have shown that Protorubradirin also inhibits Staphylococcus aureus strains and Streptococci. In infected mice, subcutaneous injection of Protorubradirin showed in vivo inhibitory efficacy against antibiotic-resistant Staphylococcus aureus strains. However, oral administration may result in a significant reduction in the activity of Protorubradirin, possibly due to faster cleavage of its C-nitroso sugar in the acidic gastric environment compared to Rubradirin .

Cat. No.	Product Name	Chemical Structure

HY-178762S

RIPK1-IN-35

RIPK1-IN-35 is a selective and orally active RIPK1 inhibitor with an IC₅₀ of 5.33 nM. RIPK1-IN-35 has a potent protective effect against necroptosis in both human and murine cells. RIPK1-IN-35 shows good therapeutic effects in both TNF-α-induced systemic inflammatory response syndrome and DSS (HY-116282C)-induced inflammatory bowel disease models. RIPK1-IN-35 can be used to the study of inflammatory diseases related to necroptosis .

HY-108974S

Drotaverine-d10 hydrochloride

Drotaverine-d₁₀ (hydrochloride) is the deuterium labeled Drotaverine hydrochloride. Drotaverine hydrochloride is a type 4 cyclic nucleotide phosphodiesterase (PDE4) inhibitor and an L-type voltage-dependent calcium channel (L-VDCC) blocker, blocks the degradation of 3',5'-cyclic adenosine monophosphate. Drotaverine hydrochloride exhibits in vivo antispasmodic efficacy without anticholinergic effects .

HY-14262S1

Vilazodone-d8 hydrochloride
Vilazodone-d₈ hydrochloride is deuterated labeled Vilazodone (HY-14262). Vilazodone (EMD 68843; SB 659746A) is a potent, selective and orally active serotonin reuptake inhibitor (SSRI) and partial 5-HT₁A receptor agonist. Vilazodone exhibits antidepressant efficacy in vivo can be used for the research of major depressive disorder (MDD) and affective disorders .

Cat. No.	Product Name		Classification

HY-146231A

SS47 TFA		PROTAC Synthesis
SS47 TFA, a PROTAC-based HPK1 degrader, exerts proteasome-mediated HPK1 degradation. The degradation of HPK1 via SS47 also significantly enhances the in vivo antitumor efficacy of BCMA CAR-T cell research. HPK1, an immunosuppressive regulatory kinase, is a promising target for cancer immunotherapies . SS47 (TFA) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-134813

MRTX1133 30+ Cited Publications		Alkynes
MRTX1133 is a noncovalent, potent, and selective alkyne-based KRAS G12D inhibitor. MRTX1133 optimally fills the switch II pocket and extends three substituents to favorably interact with the protein, resulting in an estimated K_D against KRAS G12D of 0.2 pM. MRTX1133 prevents SOS1-catalyzed nucleotide exchange and/or formation of the KRAS G12D/GTP/RAF1 complex, thereby inhibiting mutant KRAS-dependent signal transduction. MRTX1133 selectively inhibits KRAS G12D mutant, but not KRAS wild-type, tumor cells. MRTX1133 has single digit nanomolar activity in cellular assays and marked in vivo efficacy in tumor models harboring KRAS G12D mutations .

Cat. No.	Product Name		Classification